Intellia Therapeutics Says FDA Lifts Hold on Phase 3 Trial of Nexiguran Ziclumeran; Shares Rise Pre-Bell

MT Newswires Live01-27 21:35

Intellia Therapeutics (NTLA) said Tuesday that the US Food and Drug Administration has lifted a hold on the Investigational New Drug application for the Magnitude-2 phase 3 trial of Nexiguran Ziclumeran for patients with hereditary transthyretin amyloidosis with polyneuropathy.

The study will now have an increased target enrollment of 60 patients from 50 patients with hereditary transthyretin amyloidosis with polyneuropathy, according to Intellia. The primary endpoints of the study are a change in modified neuropathy impairment score and a change in serum transthyretin levels, the company said.

Shares of the company were up 20% in recent Tuesday premarket activity.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment